Lonodelestat Safely Blocks Inflammatory Marker in CF Patients in Early Trial

Lonodelestat Safely Blocks Inflammatory Marker in CF Patients in Early Trial

288524

Lonodelestat Safely Blocks Inflammatory Marker in CF Patients in Early Trial

Lonodelestat (also known as POL6014), Santhera Pharmaceuticals’ investigational therapy to treat chronic lung inflammation, was safe and effective at blocking the activity of a pro-inflammatory biomarker in patients with cystic fibrosis (CF), according to data from a Phase 1b trial. “We are very much encouraged by the trial results which support the hypothesis that lonodelestat may possess properties to counteract underlying inflammatory processes and which indicate treatment was well tolerated in patients with CF,” Dario…

You must be logged in to read/download the full post.